(Q31864811)

English

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 July 2017

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study (English)

1 reference

Europe PubMed Central

4 July 2017

0 references

0 references

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

human pregnancy

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Glueck CJ

1

1 reference

Europe PubMed Central

4 July 2017

Phillips H

2

1 reference

Europe PubMed Central

4 July 2017

Cameron D

3

1 reference

Europe PubMed Central

4 July 2017

Sieve-Smith L

4

1 reference

Europe PubMed Central

4 July 2017

Wang P

5

1 reference

Europe PubMed Central

4 July 2017

language of work or name

0 references

publication date

1 January 2001

1 reference

Europe PubMed Central

4 July 2017

Fertility and Sterility

1 reference

Europe PubMed Central

4 July 2017

75

1 reference

Europe PubMed Central

4 July 2017

46-52

1 reference

Europe PubMed Central

4 July 2017

1

1 reference

Europe PubMed Central

4 July 2017

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

The plasminogen activator system in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

The importance of diagnosing the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

The management of non-insulin-dependent diabetes during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Metformin in management of pregnant insulin-independent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Antepartum testing

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Increased frequency of genetic thrombophilia in women with complications of pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Thrombophilia-associated pregnancy wastage

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901666-6

7 January 2021

Identifiers

10.1016/S0015-0282(00)01666-6

1 reference

Europe PubMed Central

4 July 2017

1 reference

Europe PubMed Central

4 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31864811&oldid=1588402878"